Bianca A. Ulloa
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Bianca A. Ulloa has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Kathryn S. Potts
Gameto Inc., New York, USA
2 shared publications - Teresa V. Bowman
Albert Einstein College of Medicine, Department of Developmental & Molecular Biology, Bronx, NY, USA
2 shared publications Alana Lewis
Albert Einstein College of Medicine, Department of Developmental and Molecular Biology, Bronx, NY, USA
1 shared publicationAnastasia Nizhnik
Albert Einstein College of Medicine, Department of Developmental and Molecular Biology, Bronx, NY, USA
1 shared publication- Christian Mosimann
Department of Pediatrics, Section of Developmental Biology, University of Colorado School of Medicine, Anschutz Medical Campus, Aurora, USA
1 shared publication - Ellen Fraint
Nemours Children's Hospital, Wilmington, Delaware, USA
1 shared publication
Latest Publications
- Open Access
- 1 September 2021
- Published by Elsevier in Cell Reports
- Vol. 36 (11) , 109703
Definitive hematopoietic stem cells minimally contribute to embryonic hematopoiesis
- 1 September 2021
- Published by Elsevier in Cell Reports
- Vol. 36 (11) , 109703
Open AccessDefinitive hematopoietic stem cells minimally contribute to embryonic hematopoiesis
- Open Access
- 15 October 2020
- Published by Oxford University Press (OUP) in Stem Cells Translational Medicine
- Vol. 10 (3) , 337-345
Advances in preclinical hematopoietic stem cell models and possible implications for improving therapeutic transplantation
Hematopoietic stem cell transplantation (HSCT) is a treatment for many malignant, congenital, and acquired hematologic diseases. Some outstanding challenges in the HSCT field include the paucity of immunologically-matched donors, our inability to effectively expand hematopoeitic stem cells (HSCs) ex vivo, and the high infection risk during engraftment. Scientists are striving to develop protocols to generate, expand, and maintain HSCs ex vivo, however these are not yet ready for clinical application. Given these problems, advancing our understanding of HSC specification, regulation, and differentiation in preclinical models is essential to improve the therapeutic utility of HSCT. In this review, we link biomedical researchers and transplantation clinicians by discussing the potential therapeutic implications of recent fundamental HSC research in model organisms. We consider deficiencies in current HSCT practice, such as problems achieving adequate cell dose for successful and rapid engraftment, immense inflammatory cascade activation after myeloablation, and graft-vs-host disease. Furthermore, we discuss recent advances in the field of HSC biology and transplantation made in preclinical models of zebrafish, mouse, and nonhuman primates that could inform emerging practice for clinical application.
- 15 October 2020
- Published by Oxford University Press (OUP) in Stem Cells Translational Medicine
- Vol. 10 (3) , 337-345
Open AccessAdvances in preclinical hematopoietic stem cell models and possible implications for improving therapeutic transplantation
Hematopoietic stem cell transplantation (HSCT) is a treatment for many malignant, congenital, and acquired hematologic diseases. Some outstanding challenges in the HSCT field include the paucity of immunologically-matched donors, our inability to effectively expand hematopoeitic stem cells (HSCs) ex vivo, and the high infection risk during engraftment. Scientists are striving to develop protocols to generate, expand, and maintain HSCs ex vivo, however these are not yet ready for clinical application. Given these problems, advancing our understanding of HSC specification, regulation, and differentiation in preclinical models is essential to improve the therapeutic utility of HSCT. In this review, we link biomedical researchers and transplantation clinicians by discussing the potential therapeutic implications of recent fundamental HSC research in model organisms. We consider deficiencies in current HSCT practice, such as problems achieving adequate cell dose for successful and rapid engraftment, immense inflammatory cascade activation after myeloablation, and graft-vs-host disease. Furthermore, we discuss recent advances in the field of HSC biology and transplantation made in preclinical models of zebrafish, mouse, and nonhuman primates that could inform emerging practice for clinical application.